术中放疗作为乳腺癌推量治疗
本文综述术中放疗(IORT)作为乳腺癌推量治疗的技术差异与证据。最大证据来自术中电子线治疗(IOERT),单次剂量约10 Gy,中位随访6年局部复发率低于1%。IORT在精度、美容效果和患者舒适度方面优于其他推量方法,目前有两项多中心前瞻性试验正在评估其与全乳放疗的联合应用。
要点
- IOERT推量单次约10 Gy,中位随访6年局部复发率低于1%。
- G3肿瘤、三阴性乳腺癌及局部晚期新辅助后IORT局部复发率较高。
- IORT精度高、美容好、舒适度佳,可缩短术后放疗时间。
核心结论
- IORT作为乳腺癌推量治疗在IOERT技术下可获得极低局部复发率,并具有精度和美容优势。
研究设计与样本
- 本文为综述,总结不同IORT技术作为乳腺癌推量治疗的证据,最大证据来自IOERT单次剂量约10 Gy。
主要发现
- IOERT推量中位随访6年局部复发率低于1%。
- G3肿瘤、三阴性乳腺癌及局部晚期原发系统治疗后的IORT局部复发率较高,但长期(>5年)局部控制率多超过95%。
- IORT直接术中可视瘤床,避免空间或时间遗漏,允许小治疗体积和完全保留皮肤。
- IORT轻度延长手术时间,但显著缩短术后放疗时间。
关键数值与推荐
- IOERT推量单次剂量约10 Gy。
- 中位随访6年局部复发率低于1%。
- 长期(>5年)局部控制率多超过95%。
临床怎么用
- IORT推量可在手术中直接照射瘤床,适用于保乳术后推量,尤其考虑美容效果和患者舒适度时。
- IORT联合全乳外照射正在多中心前瞻性试验TARGIT-B(kV-IORT)和HIOB(IOERT后3周大分割全乳放疗)中评估。
局限性
- G3肿瘤、三阴性乳腺癌及局部晚期原发系统治疗后IORT局部复发率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of precision (by avoiding a "spatial and/or temporal miss"), cosmetic outcome and patient comfort. Direct visualisation of a tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost) study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).
引用
- Sedlmayer F, Reitsamer R, Wenz F, et al. Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol. 2017. PMID: 28103903. doi:10.1186/s13014-016-0749-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。